Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

M. C. Robson; L. G. Phillips; L. E. Robson; A. Thomason; G. F. Pierce

doi:10.1016/0140-6736(92)90143-Q

Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

M. C. Robson, L. G. Phillips, L. E. Robson, A. Thomason, G. F. Pierce

Research output: Contribution to journal › Article › peer-review

321 Scopus citations

Abstract

A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 μg/ml rPDGF-BB (0·01, 0·1, or 1·0 μg per cm² ulcer area) or placebo. Patients treated with 100 μg/ml rPDG F-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 μg/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6·4 [4·0] vs 21·8 [5·6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.

Original language	English (US)
Pages (from-to)	23-25
Number of pages	3
Journal	The Lancet
Volume	339
Issue number	8784
DOIs	https://doi.org/10.1016/0140-6736(92)90143-Q
State	Published - Jan 4 1992
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/0140-6736(92)90143-Q

Cite this

@article{129e7ae913b14c1184d1e3f87853f172,

title = "Platelet-derived growth factor BB for the treatment of chronic pressure ulcers",

abstract = "A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 μg/ml rPDGF-BB (0·01, 0·1, or 1·0 μg per cm2 ulcer area) or placebo. Patients treated with 100 μg/ml rPDG F-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 μg/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6·4 [4·0] vs 21·8 [5·6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.",

author = "Robson, {M. C.} and Phillips, {L. G.} and Robson, {L. E.} and A. Thomason and Pierce, {G. F.}",

note = "Funding Information: This work was supported by research grants AI-27741, AI-20671, and CA-39838 from the National Institutes of Health, by the Diamond Foundation, and by the Irvington Institute of Medical Research. A. C. is supported by a Pfizer postdoctoral fellowship.",

year = "1992",

month = jan,

day = "4",

doi = "10.1016/0140-6736(92)90143-Q",

language = "English (US)",

volume = "339",

pages = "23--25",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8784",

}

TY - JOUR

T1 - Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

AU - Robson, M. C.

AU - Phillips, L. G.

AU - Robson, L. E.

AU - Thomason, A.

AU - Pierce, G. F.

N1 - Funding Information: This work was supported by research grants AI-27741, AI-20671, and CA-39838 from the National Institutes of Health, by the Diamond Foundation, and by the Irvington Institute of Medical Research. A. C. is supported by a Pfizer postdoctoral fellowship.

PY - 1992/1/4

Y1 - 1992/1/4

N2 - A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 μg/ml rPDGF-BB (0·01, 0·1, or 1·0 μg per cm2 ulcer area) or placebo. Patients treated with 100 μg/ml rPDG F-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 μg/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6·4 [4·0] vs 21·8 [5·6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.

AB - A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 μg/ml rPDGF-BB (0·01, 0·1, or 1·0 μg per cm2 ulcer area) or placebo. Patients treated with 100 μg/ml rPDG F-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 μg/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6·4 [4·0] vs 21·8 [5·6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.

UR - http://www.scopus.com/inward/record.url?scp=0026595966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026595966&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(92)90143-Q

DO - 10.1016/0140-6736(92)90143-Q

M3 - Article

C2 - 1345953

AN - SCOPUS:0026595966

SN - 0140-6736

VL - 339

SP - 23

EP - 25

JO - The Lancet

JF - The Lancet

IS - 8784

ER -

Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this